Cite

    Nyström, T. et al. (2017). Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes, obesity & metabolism. 19 (6), pp. 831-841. [Online].